Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

NCT06292650 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: ZM-02-L
DRUG: ZM-02-H
PROCEDURE: ZM-02-S

Sponsor

Zhongmou Therapeutics